Evidence map›Paper›PMID 40772795›Full record

ReviewCancer2025

Controversies in metastatic hormone-sensitive prostate cancer.

Irene Tsung, Sarah E Yentz, Zachery R Reichert

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Irene TsungDivision of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.ORCID https://orcid.org/0000-0002-9105-8659
Sarah E YentzDivision of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.ORCID https://orcid.org/0000-0003-1877-8876
Zachery R ReichertDivision of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.ORCID https://orcid.org/0000-0003-0356-8796

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastatic hormone-sensitive prostate cancer (mHSPC) is an incurable phase of prostate cancer. Diagnostic tools and management strategies for this complex disease are expanding. Despite these advances, more therapies may not be the optimal approach for all patients. This review explores four major controversies surrounding mHSPC management-the role of prostate-specific membrane antigen positron emission tomography scans as diagnostic imaging, triplet therapy (androgen deprivation therapy, androgen receptor pathway inhibitor, and docetaxel chemotherapy), radiation to the prostate and/or oligo-metastases, and bone modifying agents. Critical evaluation of the data emphasizes the need for further work to determine which subgroups of patients with mHSPC benefit from each treatment. With a deeper understanding of these current issues, this review seeks to guide clinicians to refine their clinical practice to help patients achieve their best quantity and quality of life.

Indexed as

Prostatic NeoplasmsAndrogen AntagonistsBone NeoplasmsDocetaxelHumansMaleNeoplasm MetastasisPositron-Emission TomographyProstate-Specific AntigenQuality of LifeAndrogen AntagonistsDocetaxelProstate-Specific Antigenbone modifying agentcontroversiesmetastatic hormone‐sensitive prostate cancerPSMA PETradiationtriplet therapy

Identifiers

PMID40772795
PMCPMC12330319

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.